Renovation as innovation: Repurposing human antibacterial peptide LL-37 for cancer therapy
In many organisms, antimicrobial peptides (AMPs) display wide activities in innate host defense against microbial pathogens. Mammalian AMPs include the cathelicidin and defensin families. LL37 is the only one member of the cathelicidin family of host defense peptides expressed in humans. Since its d...
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2022-08-01
|
| Series: | Frontiers in Pharmacology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fphar.2022.944147/full |
| _version_ | 1798037096637661184 |
|---|---|
| author | Fatai Lu Yingkang Zhu Guodong Zhang Zunpeng Liu |
| author_facet | Fatai Lu Yingkang Zhu Guodong Zhang Zunpeng Liu |
| author_sort | Fatai Lu |
| collection | DOAJ |
| description | In many organisms, antimicrobial peptides (AMPs) display wide activities in innate host defense against microbial pathogens. Mammalian AMPs include the cathelicidin and defensin families. LL37 is the only one member of the cathelicidin family of host defense peptides expressed in humans. Since its discovery, it has become clear that they have pleiotropic effects. In addition to its antibacterial properties, many studies have shown that LL37 is also involved in a wide variety of biological activities, including tissue repair, inflammatory responses, hemotaxis, and chemokine induction. Moreover, recent studies suggest that LL37 exhibits the intricate and contradictory effects in promoting or inhibiting tumor growth. Indeed, an increasing amount of evidence suggests that human LL37 including its fragments and analogs shows anticancer effects on many kinds of cancer cell lines, although LL37 is also involved in cancer progression. Focusing on recent information, in this review, we explore and summarize how LL37 contributes to anticancer effect as well as discuss the strategies to enhance delivery of this peptide and selectivity for cancer cells. |
| first_indexed | 2024-04-11T21:21:56Z |
| format | Article |
| id | doaj.art-1aabe9d9e9b544c595dcd0a6a2f5e0ad |
| institution | Directory Open Access Journal |
| issn | 1663-9812 |
| language | English |
| last_indexed | 2024-04-11T21:21:56Z |
| publishDate | 2022-08-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Pharmacology |
| spelling | doaj.art-1aabe9d9e9b544c595dcd0a6a2f5e0ad2022-12-22T04:02:35ZengFrontiers Media S.A.Frontiers in Pharmacology1663-98122022-08-011310.3389/fphar.2022.944147944147Renovation as innovation: Repurposing human antibacterial peptide LL-37 for cancer therapyFatai LuYingkang ZhuGuodong ZhangZunpeng LiuIn many organisms, antimicrobial peptides (AMPs) display wide activities in innate host defense against microbial pathogens. Mammalian AMPs include the cathelicidin and defensin families. LL37 is the only one member of the cathelicidin family of host defense peptides expressed in humans. Since its discovery, it has become clear that they have pleiotropic effects. In addition to its antibacterial properties, many studies have shown that LL37 is also involved in a wide variety of biological activities, including tissue repair, inflammatory responses, hemotaxis, and chemokine induction. Moreover, recent studies suggest that LL37 exhibits the intricate and contradictory effects in promoting or inhibiting tumor growth. Indeed, an increasing amount of evidence suggests that human LL37 including its fragments and analogs shows anticancer effects on many kinds of cancer cell lines, although LL37 is also involved in cancer progression. Focusing on recent information, in this review, we explore and summarize how LL37 contributes to anticancer effect as well as discuss the strategies to enhance delivery of this peptide and selectivity for cancer cells.https://www.frontiersin.org/articles/10.3389/fphar.2022.944147/fullantimicrobial peptidescathelicidin (LL37)hCAP18LL37canceranticancer |
| spellingShingle | Fatai Lu Yingkang Zhu Guodong Zhang Zunpeng Liu Renovation as innovation: Repurposing human antibacterial peptide LL-37 for cancer therapy Frontiers in Pharmacology antimicrobial peptides cathelicidin (LL37) hCAP18 LL37 cancer anticancer |
| title | Renovation as innovation: Repurposing human antibacterial peptide LL-37 for cancer therapy |
| title_full | Renovation as innovation: Repurposing human antibacterial peptide LL-37 for cancer therapy |
| title_fullStr | Renovation as innovation: Repurposing human antibacterial peptide LL-37 for cancer therapy |
| title_full_unstemmed | Renovation as innovation: Repurposing human antibacterial peptide LL-37 for cancer therapy |
| title_short | Renovation as innovation: Repurposing human antibacterial peptide LL-37 for cancer therapy |
| title_sort | renovation as innovation repurposing human antibacterial peptide ll 37 for cancer therapy |
| topic | antimicrobial peptides cathelicidin (LL37) hCAP18 LL37 cancer anticancer |
| url | https://www.frontiersin.org/articles/10.3389/fphar.2022.944147/full |
| work_keys_str_mv | AT fatailu renovationasinnovationrepurposinghumanantibacterialpeptidell37forcancertherapy AT yingkangzhu renovationasinnovationrepurposinghumanantibacterialpeptidell37forcancertherapy AT guodongzhang renovationasinnovationrepurposinghumanantibacterialpeptidell37forcancertherapy AT zunpengliu renovationasinnovationrepurposinghumanantibacterialpeptidell37forcancertherapy |